プロゲステロン市場：タイプ、投与方法、用途別-2025年～2030年の世界予測

プロゲステロン市場は、2023年に13億米ドルと評価され、2024年には14億7,000万米ドルに達すると予測され、CAGR 13.39％で成長し、2030年には31億4,000万米ドルに達すると予測されています。

生殖系に不可欠なホルモンであるプロゲステロンは、月経周期の調整、妊娠の維持に重要な役割を果たしており、様々な治療に応用されています。プロゲステロンの必要性は、その生理的役割にとどまらず、ホルモン補充療法、避妊薬、月経障害や特定のがんの治療にも極めて重要です。その多様な有用性を反映し、最終用途の範囲は医薬品、バイオテクノロジー、さらには獣医学分野にまで及んでいます。市場の洞察によると、生殖に関する健康意識の高まり、婦人科疾患の増加、ドラッグデリバリーシステムの進歩がプロゲステロン市場の極めて重要な成長要因となっています。バイオアイデンティカルホルモンや天然プロゲステロンに対する需要の高まりは、新たな治療領域における用途拡大の可能性と同様に、大きな市場機会を示しています。企業は、革新的な製剤やドラッグデリバリー技術に投資し、規制基準の遵守を徹底し、ホルモン療法に関する消費者教育に注力することで、こうした機会を捉えることができます。しかし、市場に課題がないわけではありません。厳しい規制要件、合成品に伴う副作用、代替療法との競合などが、顕著な制約となっています。新興市場における価格敏感性や、原材料の複雑なサプライチェーンダイナミクスも成長の可能性を妨げています。これらの課題を克服するためには、より安全で効率的な合成製剤やバイオアイデンティカル製剤の研究を増やす必要があります。さらに、個別化医療とバイオテクノロジーの進歩は、イノベーションのための肥沃な土壌を提供しています。市場の競争は激しいですが、戦略的提携やニッチ市場への注力、製品の有効性と安全性を向上させる技術の活用などを通じて、こうした複雑な状況を乗り切ることができる企業にとっては、チャンスに満ちています。規制の変化を予測し、消費者の嗜好に合った製品を提供することで、企業は成長を維持し、プロゲステロン市場の新たな動向を活用することができます。

市場力学：急速に進化するプロゲステロン市場の主要市場インサイトを公開

プロゲステロン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

ポーターのファイブフォース：プロゲステロン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：プロゲステロン市場における外部からの影響の把握

外部マクロ環境要因は、プロゲステロン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：プロゲステロン市場における競合情勢の把握

プロゲステロン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：プロゲステロン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、プロゲステロン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：プロゲステロン市場における成功への道筋を描く

プロゲステロン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価をします。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 無月経、乳がん、エイズの罹患率の上昇
    • 世界中で女性の不妊率が上昇
    • 婦人科治療の多様化による需要増加
  • 抑制要因
    • プロゲステロンとプロゲスチンの副作用に関する懸念
  • 機会
    • 医療分野における技術進歩
    • 進行中の研究開発活動
  • 課題
    • ホルモン療法に関する認識不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済的
  • 社会的
  • 技術的
  • 法的
  • 環境的

第6章 プロゲステロン市場：タイプ別

• 天然プロゲステロン
• 合成プロゲステロン

第7章 プロゲステロン市場：投与方法別

• 注射剤
• 経口剤
• 懸濁液

第8章 プロゲステロン市場：用途別

• 避妊
• 子宮機能不全出血
• 子宮内膜がん
• 過形成前駆病変
• 月経周期の調整

第9章 南北アメリカのプロゲステロン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のプロゲステロン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのプロゲステロン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alkem Laboratories Ltd.
• Aquatic Remedies Pvt. Ltd
• Bionpharma, Inc.
• Blubell Pharma Group Company
• Cadila Pharmaceuticals
• Caesar & Loretz Gmbh
• Cipla Limited
• Estrellas Life Sciences Private Limited
• Fagron Industry
• Glenmark Pharmaceuticals
• Intas Pharmaceuticals Ltd.
• Lupin Limited
• Shaanxi Hanjiang Pharmaceutical Group Co., Ltd.
• Shandong Octagon Chemicals Limited
• Shanghai Yijing Industrial Co., Ltd.
• Sigmak Life Sciences
• Sofgen Pharmaceuticals Llc
• Teva Pharmaceuticals Industries Ltd.
• Virtus Pharmaceuticals Llc
• Wuhan Honor Bio-Pharm Co., Ltd.

LIST OF FIGURES

• FIGURE 1. PROGESTERONE MARKET RESEARCH PROCESS
• FIGURE 2. PROGESTERONE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PROGESTERONE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PROGESTERONE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PROGESTERONE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PROGESTERONE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PROGESTERONE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PROGESTERONE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PROGESTERONE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PROGESTERONE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PROGESTERONE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PROGESTERONE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PROGESTERONE MARKET DYNAMICS
• TABLE 7. GLOBAL PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PROGESTERONE MARKET SIZE, BY SUSPENDED FORM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PROGESTERONE MARKET SIZE, BY DYSFUNCTIONAL UTERINE BLEEDING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PROGESTERONE MARKET SIZE, BY HYPERPLASTIC PRECURSOR LESIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PROGESTERONE MARKET SIZE, BY REGULATION OF THE MENSTRUAL CYCLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 32. CANADA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES PROGESTERONE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CHINA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 49. CHINA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. INDIA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 52. INDIA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ITALY PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 104. ITALY PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. POLAND PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 116. POLAND PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. QATAR PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 119. QATAR PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM PROGESTERONE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. PROGESTERONE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. PROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2023

The Progesterone Market was valued at USD 1.30 billion in 2023, expected to reach USD 1.47 billion in 2024, and is projected to grow at a CAGR of 13.39%, to USD 3.14 billion by 2030.

Progesterone, a vital hormone in the reproductive system, plays a critical role in regulating the menstrual cycle, maintaining pregnancy, and has applications in various medical treatments. The necessity of progesterone extends beyond its physiological roles; it's crucial for hormone replacement therapy, contraceptives, and treatment of menstrual disorders and certain cancers. The end-use scope spans across pharmaceuticals, biotechnology, and even veterinary sectors, reflecting its diverse utility. Market insights indicate that the growing awareness of reproductive health, increasing gynecological disorders, and advancements in drug delivery systems are pivotal growth factors in the progesterone market. The rising demand for bio-identical hormones and natural progesterone represents significant market opportunities, as does the potential for expanding applications in newer therapeutic areas. Companies could capture these opportunities by investing in innovative drug formulations and delivery technologies, ensuring compliance with regulatory standards, and focusing on consumer education regarding hormone therapies. However, the market is not without challenges. Stringent regulatory requirements, side effects associated with synthetic variants, and competition from alternative therapies pose notable limitations. Price sensitivity in emerging markets and complex supply chain dynamics for raw materials also hinder growth potential. To overcome these challenges, there's a need for increased research into safer, more efficient synthetic and bio-identical progesterone formulations. Moreover, advancements in personalized medicine and biotechnology present fertile ground for innovation. The nature of the market is competitive yet ripe with opportunities for businesses that can navigate these complexities through strategic partnerships, focusing on niche markets, and leveraging technology to improve product efficacy and safety. By anticipating regulatory changes and aligning product offerings with consumer preferences, companies can sustain growth and capitalize on emerging trends in the progesterone market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Progesterone Market

The Progesterone Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of amenorrhea, breast cancer, and AIDS
  • Growing female infertility rates all over the globe
  • Increasing demand owing to different gynecological treatment
• Market Restraints
  • Concern associated with side effects of progesterone and progestin
• Market Opportunities
  • Technological advancements in the medical field
  • Ongoing research and development activities
• Market Challenges
  • Lack of awareness about hormone therapy

Porter's Five Forces: A Strategic Tool for Navigating the Progesterone Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Progesterone Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Progesterone Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Progesterone Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Progesterone Market

A detailed market share analysis in the Progesterone Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Progesterone Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Progesterone Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Progesterone Market

A strategic analysis of the Progesterone Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Progesterone Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Aquatic Remedies Pvt. Ltd, Bionpharma, Inc., Blubell Pharma Group Company, Cadila Pharmaceuticals, Caesar & Loretz Gmbh, Cipla Limited, Estrellas Life Sciences Private Limited, Fagron Industry, Glenmark Pharmaceuticals, Intas Pharmaceuticals Ltd., Lupin Limited, Shaanxi Hanjiang Pharmaceutical Group Co., Ltd., Shandong Octagon Chemicals Limited, Shanghai Yijing Industrial Co., Ltd., Sigmak Life Sciences, Sofgen Pharmaceuticals Llc, Teva Pharmaceuticals Industries Ltd., Virtus Pharmaceuticals Llc, and Wuhan Honor Bio-Pharm Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Progesterone Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Natural Progesterone and Synthetic Progesterone.
• Based on Mode of Delivery, market is studied across Injectable, Oral, and Suspended Form.
• Based on Application, market is studied across Contraception, Dysfunctional Uterine Bleeding, Endometrial Cancer, Hyperplastic Precursor Lesions, and Regulation of the Menstrual Cycle.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of amenorrhea, breast cancer, and AIDS
    • 5.1.1.2. Growing female infertility rates all over the globe
    • 5.1.1.3. Increasing demand owing to different gynecological treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Concern associated with side effects of progesterone and progestin
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in the medical field
    • 5.1.3.2. Ongoing research and development activities
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of awareness about hormone therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Progesterone Market, by Type

• 6.1. Introduction
• 6.2. Natural Progesterone
• 6.3. Synthetic Progesterone

7. Progesterone Market, by Mode of Delivery

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Suspended Form

8. Progesterone Market, by Application

• 8.1. Introduction
• 8.2. Contraception
• 8.3. Dysfunctional Uterine Bleeding
• 8.4. Endometrial Cancer
• 8.5. Hyperplastic Precursor Lesions
• 8.6. Regulation of the Menstrual Cycle

9. Americas Progesterone Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Progesterone Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Progesterone Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alkem Laboratories Ltd.
• 2. Aquatic Remedies Pvt. Ltd
• 3. Bionpharma, Inc.
• 4. Blubell Pharma Group Company
• 5. Cadila Pharmaceuticals
• 6. Caesar & Loretz Gmbh
• 7. Cipla Limited
• 8. Estrellas Life Sciences Private Limited
• 9. Fagron Industry
• 10. Glenmark Pharmaceuticals
• 11. Intas Pharmaceuticals Ltd.
• 12. Lupin Limited
• 13. Shaanxi Hanjiang Pharmaceutical Group Co., Ltd.
• 14. Shandong Octagon Chemicals Limited
• 15. Shanghai Yijing Industrial Co., Ltd.
• 16. Sigmak Life Sciences
• 17. Sofgen Pharmaceuticals Llc
• 18. Teva Pharmaceuticals Industries Ltd.
• 19. Virtus Pharmaceuticals Llc
• 20. Wuhan Honor Bio-Pharm Co., Ltd.